

Acridine Derivatives. IV [1]. Synthesis, Molecular Structure, and Antitumor Activity of the Novel 9-Anilino-2,3-methylenedioxyacridines

Michio Kimura*

Department of Pharmacy, Kyoto University Hospital,
Faculty of Medicine, Kyoto University,
Sakyo-ku, Kyoto 606, Japan

Akira Kato and Ichizo Okabayashi

Niigata College of Pharmacy, 5-13-2 Kamishin'ei-cho,
Niigata 950-21, Japan

Received May 20, 1991

In the biological and physical investigation of a new class of deoxyribonucleic acid (DNA)-intercalating antitumor agents, novel 9-anilino-2,3-methylenedioxyacridines (twelve compounds) have been synthesized and evaluated for the activity against L1210 leukemia *in vivo*. A few of them possessed the same potency of the antitumor activity as 4'-(9-acridinylamino)methanesulfonyl-*m*-anisidine (amsacrine, *m*-AMSA), which is an important antitumor agent in clinical use. The molecular structure of a typical one, **9a** in this series have been determined by the X-ray diffraction method using a single crystal. The results of this X-ray investigation have shown that the new class of acridine derivatives have the methylenedioxy group fused at the 2- and 3-positions of the acridine ring.


J. Heterocyclic Chem., **29**, 73 (1992).

We have been studying the properties of DNA-binding drugs possessing antitumor activities to develop potential antitumor agents. In the previous paper [1], we have reported that novel acridinyl-substituted uracils were synthesized by the enamine reaction between 6-aminouracil and 9-chloroacridines, and they had antitumor activity as well as antibacterial and antifungal activity. It can fairly be argued that most aspects of the total cancer problem revolve around the abnormal behavior of DNA, and antitumor agents suppress it by interacting with DNA. The DNA-binding drugs developed are known to have a wide



variety of binding modes, but they may be divided into two main classes; (1) intercalative and (2) non-intercalative DNA binding drugs. Within each class, some compounds interact non-covalently with DNA, and others bind first reversibly, and then interact covalently with DNA. DNA has the reversible binding ability to include planar aromatic molecules which can be inserted between the base pairs of the double helix [2-4]. On the other hand, the intercalation of some molecules within DNA is considered to be important in mutagenesis, carcinogenesis, and the medicinal activities of antibacterial, antiparasitic, and

Scheme 1

Method A



Method B



antineoplastic drugs [5-8]. The acridine derivatives known as DNA intercalators, such as acridine orange [8], quinacrine [9], terpyridine platinum [10], ethidium [11], 9-aminoacridine [12], proflavine [13], and ellipticine [14] are effective in chromosome binding studies in cytogenecis. Furthermore, the intercalation and the subsequent unwinding of the DNA double helix has been shown to be an important tool in the study of the superhelicity [15-19]. A series of 4'-(9-acridinylamino)methanesulfonyl-*m*-anisidine (amsacrine, *m*-AMSA) [20-22] analogues has been shown to exhibit excellent anticancer activity in clinical use an intercalator within the DNA duplex. It is thus of great interest to find new types of intercalators possessing potent antitumor activities and to understand in detail the manner of their binding modes within the confines of the double-helical structure of DNA.

In this work, we have synthesized new types of acridines fused with a methylenedioxy group at the 2- and 3-positions of the acridine ring, which have shown the same potency of antitumor activities as *m*-AMSA in the L1210 antitumor test (as in biological section). The molecular structure of the typical product (**9a** in Scheme 1) was established by X-ray diffraction studies using a single crystal. We further synthesized its derivatives which vary in substituent size and electronic character in order to examine their biological activities and to know how they are perturbed by substituent changes on the acridine nucleus. The novel 9-anilino-2,3-methylenedioxyacridine **9** were synthesized by the reaction process shown in Scheme 1. The diphenylamines **3** and **6** used as intermediates were prepared by two different methods (method A and B in Scheme 1). The 2-anilino-4,5-methylenedioxybenzoic acid derivatives **3** were prepared by direct nucleophilic displacement (Ullmann reaction) [23,24] of 2-chloro-4,5-methylenedioxybenzoic acid (**1**) by substituted anilines **2** (method A). Similarly, alternative diphenylamines **6** were also obtained by the Ullmann reaction between 3,4-methylenedioxyaniline (**4**) and substituted 2-chlorobenzoic acids

5 (method B). These reaction processes are outlined in Scheme 1. Method A proceeded with a range of 15-25% yields to obtain the desired 2-anilino-4,5-methylenedioxybenzoic acids **3**, but method B gave **6** in lower yield (less than 20%). In addition, the diphenylamines **3** were easily purified by the steam distillation after the reaction of method A, and further purification processes were unnecessary for the next reaction step. On the other hand, the 3',4'-methylenedioxyanilinobenzoic acids **6** in the method B were obtained as a mixture of the decomposed tar **4**, which required further purification processes for pure products **6**. The synthesis of the starting material **1** requires two reaction steps [25] from piperonal whose overall yield is less than 20%. Method B has the advantage that 3,4-methylenedioxyaniline (**4**) is commercially available, but the cost of **4** is high. Considering these reasons, in this report, method A is mainly used to obtain 2-anilino-4,5-methylenedioxybenzoic acids **3**. The ten methylenedioxybenzoic acids synthesized by the method A and B are listed in Table 1. By using **3** and **6**, the acridine ring formation was effected in many cases with phosphoryl chloride or thionyl chloride to provide a 2,3-methylenedioxy-9-chloroacridines **7** directly without isolation of the acridines prepared as an intermediate [26]. In many cases, this ring closure proceeded rapidly with refluxing in phosphoryl chloride solution by taking 2 hours and changed to a green color to give the desired 9-chloro-2,3-methylenedioxyacridines **7** in high yields. When the ring formation with phosphoryl chloride was not desirable, this reaction was effected with either sulfuric acid, PPA or PPE to give the 9(10*H*)-acridones, which were then converted to the desired 9-chloroacridines with thionyl chloride/DMF as usual [1]. These reaction product 9-chloro-2,3-methylenedioxyacridine derivatives **7** can be used for the next step without further purification. The 9-chloro-2,3-methylenedioxyacridine **7** was then coupled with the appropriate arylamine bearing CH₃O, NHSO₂CH₃ or CH₃ groups as side chains to provide the desired new type of acridines **9**.

Table 1
Physical Data of Methylenedioxybenzoic Acids **3** and **6**

No.	R ₁ or R ₂	-O-CH ₂ -O-	¹ H-NMR (Me ₂ SO-d ₆)		CH ₃	or	CH ₃ O	IR (KBr) (cm ⁻¹)
			NH	COOH				
3a	H	5.95	4.82	9.43				3260 1660 1630
3c	2'-CH ₃	6.03	2.34	9.83	2.26			3300 1670 1640
3d	3'-CH ₃	6.02	4.85	9.52	2.33			3300 1670 1630
3e	4'-CH ₃	5.88	4.90	9.65	2.32			3250 1660 1635
3f	4'-Cl	6.03	5.02	9.82				3320 1660 1640
3h	2'-CH ₃ O	6.05	5.09	9.83			3.80	3300 1670 1630
3j	3'-CH ₃ O	6.03	4.83	9.58			3.92	3350 1680 1650
6b	4-Cl	5.99	4.83	9.45				3300 1700 1650
6g	3-Cl	6.05	4.93	9.35				3250 1680 1630
6i	5-CH ₃ O	6.05	4.80	9.90			3.95	3300 1700 1630

Table 2
Physical Data of 9-Anilino-2,3-methylenedioxyacridines 9

No. [a]	R ₁ or R ₂	R ₃	R ₄	acridine ring -O-CH ₂ -O-	¹ H-NMR (Me ₂ SO-d ₆) phenyl ring CH ₃ O	SO ₂ CH ₃	CH ₃ or CH ₃ O	IR (KBr) (cm ⁻¹)
9a	H	CH ₃ O	NHSO ₂ CH ₃	6.29	3.51	3.08		3830 3740 3400 1640 1610 1570
9b	6-Cl	CH ₃ O	NHSO ₂ CH ₃	6.32	3.48	3.10		3820 3730 3450 1650 1620 1580
9c	5-CH ₃	CH ₃ O	NHSO ₂ CH ₃	6.30	3.51	3.09	2.51	3850 3740 3450 1650 1630 1600
9d	6-CH ₃	CH ₃ O	NHSO ₂ CH ₃	6.29	3.39	3.09	3.04	3850 3740 3430 1700 1640 1610
9e	7-CH ₃	CH ₃ O	NHSO ₂ CH ₃	6.28	3.48	3.08	2.33	3850 3740 3430 1650 1640 1610
9f	7-Cl	CH ₃ O	NHSO ₂ CH ₃	6.32	3.51	3.09		3850 3740 3450 1650 1610 1560
9g	5-Cl	CH ₃ O	NHSO ₂ CH ₃	6.31	3.51	3.07		3850 3730 3420 1640 1610 1550
9h	5-CH ₃ O	CH ₃ O	NHSO ₂ CH ₃	6.23	3.40	2.99	2.42	3830 3730 3500 1650 1610 1580
9i	7-CH ₃ O	CH ₃ O	NHSO ₂ CH ₃	6.21	3.44	2.99	2.52	3850 3740 3520 1650 1620 1550
9j	6-CH ₃ O	CH ₃ O	NHSO ₂ CH ₃	6.30	3.43	3.01	2.31	3850 3740 3430 1630 1600 1520
9k	H	H	CH ₃	6.30			3.05	3830 3750 3400 1645 1590 1570
9l	H	H	H	6.30				3825 3750 3390 1640 1600 1570

[a] For the hydrochlorides of compounds 9a-l.

After the coupling reaction, the novel compounds **9** were obtained in the crystalline state which were purified by recrystallization from methanol or ethanol by the addition of a small amount of water. The molecular structure of a typical product **9a** of this novel acridine series was determined by X-ray analysis using a single crystal of **9a**. For twelve compounds listed in Table 2, the analytical and spectroscopic data are in good agreement with the structures.

In the proton nuclear magnetic resonance (¹H-nmr) spectra measured at 200 MHz (in deuteriodimethyl sulfoxide), the singlet lines at 6.0-6.5 are assignable to the methylenedioxy group on the acridine ring, the sharp singlet signals of the methoxy group at 3.0-3.5, and the multiplet signals at 7.3-8.6 assignable to the acridine ring protons were characteristic. The infrared spectra ir (potassium bromide) indicated a broad absorption band at 3800 and 3700 cm⁻¹ with a shoulder at 3500 cm⁻¹, and very strong peaks at 1700, 1600 and 1500 cm⁻¹ (Table 2). The mass spectra (ms) of products **9** exhibited a strong molecular ion M⁺ corresponding to the molecular weight, and a typical peak due to M⁺-SO₂CH₃, and M⁺-SO₂CH₃-NH.

Biological Activity and Molecular Structure.

In the series of 9-anilino-2,3-methylenedioxyacridines **9**, the substituent effects on overall molecular lipophilic-hydrophilic balance and the electronic and steric effects of substituent groups are important factors for the antitumor biological activity. In consideration of these effects, twelve

Table 3
Antitumor Activities *in vivo*

No.	Dose (mg/kg)	Median survival days (M. S. D.)	T/C (%)
Control	10 x 2	10.67	100
m-AMSA	10 x 2	20.50	192
9a	10 x 2	16.23	152
9b	10 x 2	14.38	135
9c	10 x 2	13.57	127
9d	10 x 2	13.43	126
9e	10 x 2	10.71	100
9f	10 x 2	10.29	96
9g	10 x 2	10.71	100
9h	10 x 2	9.43	88
9i	10 x 2	10.00	94
9j	10 x 2	15.14	142

Mice were given the compound (10 mg/kg) intraperitoneally twice a day, and on day 2, 4 and 6 after intraperitoneal injection of L1210 (2 x 10⁵/mouse).

Table 4a
Atomic Parameters for Non-hydrogen Atoms

Estimated standard deviations are given in parentheses. Beq is isotropic equivalent of the anisotropic thermal parameter (Hamilton, 1959) [36]

atom	x	y	z	Beq
C1	0.8818(2)	1.3133(2)	0.3050(2)	2.38(7)
C2	0.8047(2)	1.3012(2)	0.2162(2)	2.49(7)
C3	0.8430(2)	1.3234(2)	0.0795(2)	2.64(7)
C4	0.9584(2)	1.3591(2)	0.0304(2)	2.35(7)
C5	1.0419(2)	1.3789(2)	0.1251(2)	2.31(7)
N6	1.1583(3)	1.4284(3)	0.0869(3)	2.33(7)
C7	1.2436(2)	1.4676(2)	0.1799(2)	2.46(7)
C8	1.3595(3)	1.5318(3)	0.1412(3)	4.77(7)
C9	1.4466(2)	1.5710(2)	0.2335(2)	3.45(7)
C10	1.4200(2)	1.5474(2)	0.3684(2)	3.19(7)
C11	1.3077(2)	1.4847(2)	0.4068(2)	2.80(7)
C12	1.2152(2)	1.4434(2)	0.3160(2)	2.38(7)
C13	1.0962(2)	1.3742(2)	0.3480(2)	2.31(7)
C14	1.0063(2)	1.3536(2)	0.2615(2)	2.26(7)
O15	0.6835(2)	1.2671(2)	0.2366(2)	1.24(7)
C16	0.6408(2)	1.2782(2)	0.1195(2)	3.10(7)
O17	0.7472(2)	1.3052(2)	0.0151(2)	2.93(7)
N18	1.0732(2)	1.3365(2)	0.4667(2)	2.44(7)
C19	0.9815(2)	1.2288(2)	0.4831(2)	2.16(7)
C20	0.9739(2)	1.1025(2)	0.3698(2)	2.33(7)
C21	0.8942(2)	0.9970(2)	0.3953(2)	2.55(7)
C22	0.8228(2)	1.0188(2)	0.5369(2)	2.51(7)
C23	0.8263(2)	1.1439(2)	0.6474(2)	2.89(7)
C24	0.9075(2)	1.2486(2)	0.6201(2)	2.73(7)
O25	1.0474(2)	1.0910(2)	0.2371(2)	3.18(7)
C26	1.0494(2)	0.9611(2)	0.1262(2)	3.86(7)
N27	0.7514(3)	0.9036(3)	0.5579(3)	3.44(7)
S28	0.6328(3)	0.8956(3)	0.6789(3)	2.93(7)
O29	0.6562(2)	0.9953(2)	0.8262(2)	5.52(7)
O30	0.5234(3)	0.9297(3)	0.6150(3)	8.01(7)
C31	0.5955(2)	0.7623(2)	0.6603(2)	2.04(7)
O32	0.3254(2)	1.1721(2)	0.9378(2)	15.00(7)
C33	0.3365(2)	1.0618(2)	0.9106(2)	10.52(7)
Cl34	1.2232(2)	1.3695(3)	1.7307(2)	2.94(7)

derivatives **9a-9l** with electron-donating or electron-withdrawing substituents on the acridine ring as shown in Table 2 were prepared. Ten compounds (Table 3) with various substituents on the acridine ring were tested for




Figure 1. ORTEP drawing of compound **9a**. Thermal ellipsoids are drawn at the 50% probability level.

Table 4b
Fractional Coordinates and Isotropic Thermal Parameters (A**2)
for Hydrogen Atoms

atom	x	y	z	Biso
HC1	0.851(4)	1.298(4)	0.409(4)	2.5
HC4	0.987(4)	1.372(4)	-0.074(4)	2.6
HN6	1.182(4)	1.433(4)	-0.018(4)	9.2
HC8	1.379(4)	1.550(4)	0.041(5)	3.6
HC9	1.536(4)	1.621(5)	0.207(5)	3.1
HC10	1.487(5)	1.580(5)	0.437(5)	2.6
HC11	1.290(4)	1.468(4)	0.507(4)	2.8
HC16A	0.590(4)	1.192(4)	0.066(4)	8.6
HC16B	0.575(4)	1.328(4)	0.167(4)	7.0
HN18	1.140(5)	1.368(5)	0.540(5)	3.7
HC21	0.887(4)	0.900(4)	0.307(4)	3.3
HC23	0.771(4)	1.160(4)	0.748(4)	2.7
HC24	0.915(4)	1.346(4)	0.704(4)	2.3
HC26	1.112(4)	0.969(4)	0.056(4)	3.6
HN27	0.752(5)	0.810(5)	0.468(5)	4.0
HC31A	0.620(4)	0.773(4)	0.767(4)	3.5
HC31B	0.624(4)	0.721(4)	0.602(4)	6.1
HC31C	0.535(4)	0.737(4)	0.655(4)	6.0
HC33A	0.378(4)	1.068(4)	1.003(4)	3.5
HC33B	0.262(4)	0.977(4)	0.898(4)	5.0
HC33C	0.395(4)	1.026(4)	0.805(4)	5.0

antitumor activity by measuring the life extension assay with L1210 leukemia (as shown in the Experimental). Some variants **9h** and **9i** provided only fair-potency or less active properties in the antitumor effects. However, the Cl, CH₃, or CH₃O groups at the 5- or 6-positions of the acridine ring provided agents with significant activity. It is clear from these biological activities that these variants have the best combinations of 6-Cl and 2,3-methylenedioxy groups, and that less active agents result from other placement of the substituents.

The structure of compound **9a** determined by the X-ray diffraction method has shown the novel acridine derivatives fused by methylenedioxy group, which is obtained by the acridine ring formation reaction using corresponding anilino benzoic acid and phosphoryl chloride. The molecular structure and the atom labeling of **9a** are presented by the ORTEP [27] drawing in Figure 1. The bond distances and angles are given in Table 5 together with estimated




Figure 2. Formulae of ICR series compounds.

Table 5
Bond Lengths (Å) and valence angles (degree)

Bond	Length	Bond	Length
C1 - C2	1.344(4)	C1 - C14	1.430(3)
C2 - C3	1.418(3)	C2 - O15	1.362(3)
C3 - C4	1.342(3)	C3 - O17	1.347(4)
C4 - C5	1.416(4)	C5 - N6	1.358(4)
C5 - C14	1.433(3)	N6 - C7	1.361(4)
C7 - C8	1.405(4)	C7 - C12	1.425(3)
C8 - C9	1.373(4)	C9 - C10	1.411(3)
C10 - C11	1.366(3)	C11 - C12	1.411(3)
C12 - C13	1.437(3)	C13 - C14	1.417(4)
C13 - N18	1.360(3)	O15 - C16	1.428(4)
C16 - O17	1.473(3)	N18 - C19	1.433(3)
C19 - C20	1.393(2)	C19 - C24	1.385(3)
C20 - C21	1.388(3)	C20 - O25	1.360(3)
C21 - C22	1.404(3)	C22 - C23	1.379(3)
C22 - N27	1.428(4)	C23 - C24	1.394(3)
O25 - C26	1.429(3)	N27 - S28	1.620(4)
S28 - O29	1.423(3)	S28 - O30	1.780(6)
S28 - C31	1.423(4)	O32 - C33	1.240(4)

Bond	Angle	Bond	Angle
C2 - C1 - C14	118.4(2)	C1 - C2 - C3	122.2(2)
C1 - C2 - O15	128.6(2)	C3 - C2 - O15	109.2(3)
C2 - C3 - C4	122.5(2)	C2 - C3 - O17	109.3(2)
C4 - C3 - O17	128.2(2)	C3 - C4 - C5	116.7(2)
C4 - C5 - N6	118.0(2)	C4 - C5 - C14	122.0(2)
N6 - C5 - C14	119.9(3)	C5 - N6 - C7	122.9(3)
N6 - C7 - C8	119.8(3)	N6 - C7 - C12	120.0(2)
C8 - C7 - C12	120.2(2)	C7 - C8 - C9	120.4(3)
C8 - C9 - C10	120.1(2)	C9 - C10 - C11	120.0(2)
C10 - C11 - C12	121.9(2)	C7 - C12 - C11	117.4(2)
C7 - C12 - C13	118.0(2)	C11 - C12 - C13	124.6(2)
C12 - C13 - C14	119.6(2)	C12 - C13 - N18	117.9(2)
C14 - C13 - N18	122.4(2)	C1 - C14 - C5	118.0(2)
C1 - C14 - C13	123.9(2)	C5 - C14 - C13	118.2(2)
C2 - O15 - C16	108.0(2)	O15 - C16 - O17	105.7(2)
C3 - O17 - C16	107.3(2)	C13 - N18 - C19	126.3(2)
N18 - C19 - C20	120.9(2)	N18 - C19 - C24	119.2(2)
C20 - C19 - C24	119.6(2)	C19 - C20 - C21	120.1(2)
C19 - C20 - O25	116.3(2)	C21 - C20 - O25	123.6(2)
C20 - C21 - C22	119.3(2)	C21 - C22 - C23	120.9(2)
C21 - C22 - N27	115.4(2)	C23 - C22 - N27	123.7(2)
C22 - C23 - C24	118.8(2)	C19 - C24 - C23	121.1(2)
C20 - O25 - C26	116.8(2)	C22 - N27 - S28	126.2(3)
N27 - S28 - O29	109.4(2)	N27 - S28 - O30	106.1(3)
N27 - S28 - C31	105.4(2)	O29 - S28 - O30	108.1(3)
O29 - S28 - C31	119.3(3)	O30 - S28 - C31	107.9(2)

Table 6
Comparison of Molecular Geometry Between **9a** and *m*-AMSA

	9a	<i>m</i> -AMSA [37]
Average C-C bond of ring A	1.397Å	1.398 Å
Average C-C bond of ring B	1.399	1.399
Average C-C bond of ring C	1.391	1.349
C9-N bond	1.360	1.359
Dihedral angle between ring A and B	11.84°	5.0°
Dihedral angle between acridine and phenyl rings	109.3°	132.0°

standard deviations. The present studies have shown that the part of methylenedioxyacridine ring is completely planar. Using the structure of the compound **9a** elucidated by the X-ray diffraction method, the conformation was compared with those of *m*-AMSA (Table 6). As shown in Table 6, the average C-C distances of two benzene rings of the acridine nucleus are 1.397 and 1.399 Å, respectively, while that of the C-N distances of the acridine nucleus is 1.360 Å. On the other hand, the aniline part has average values of 1.391 Å in the C-C bond and 1.360 Å in the C-N bond. These values are normal, and the bond distances of the two benzene rings of the acridine nucleus are exactly equivalent within experimental errors. The derivatives from the least-squares planes through portions of the molecule are calculated, and the dihedral angle between the least-squares planes defined by the acridine ring and the aniline part is 109.3°. The calculated dihedral angle is 11.84° between the best planes through the outer rings (A and B in Figure 1) of the acridine ring system; these are compared with values of 5° for *m*-AMSA, 8° for quinacrine [1], 4.9° for ICR-191-OH [28], 7.5° for ICR-171-OH [29], 10.7° for ICR-170-OH [30], and 12.5° for ICR-449-OH [31]. The formulae of the above ICR compounds are shown in Figure 2. In these series of acridines, it seems that the more potent biological activities, such as antitumor and mutagenic activities, are caused by the flatter ring system and are better stacking ring system as intercalators to DNA. It is likely that compound **9a** and *m*-AMSA intercalates within the DNA duplex in a similar manner, and thus have similar interaction with the nucleic acid bases which are required for the antitumor activity.

EXPERIMENTAL

Spectroscopy.

The ¹H-nmr spectra were measured in deuteriodimethyl sulfoxide solution in 5 mm tubes on a JEOL FX-200 spectrometer. Chemical shifts were recorded as units relative to tetramethylsilane (δ 0.0) as the internal standard. The ir spectra were measured on a JASCO A-3 spectrometer. The EI mass spectra were obtained with a Hitachi RMU-7MG mass spectrometer.

The melting points were measured on a Yanagimoto micro-melting point apparatus and are uncorrected.

General Procedure for the Reaction of Benzoic Acids **1** and **5** with Anilines **2** and **4**.

2-Anilino-4,5-methylenedioxybenzoic Acid (**3a**).

A mixture of 16 g (0.08 mole) of 2-chloro-4,5-methylenedioxybenzoic acid [25], 9.3 g (0.1 mole) of freshly distilled aniline, 11.1 g (0.08 mole) of anhydrous potassium carbonate, and 0.4 g of copper bronze was heated under reflux with stirring for 6 hours. The 35% potassium hydroxide solution (50 ml) was added, and the excess aniline was removed by steam distillation. The residue was filtered and the filtrate was acidified with concentrated hydrochloric acid to give a purple solid, which was recrystallized from alcohol to yield 4.8 g (21%), mp 160-162°; ir (potassium bromide):

ν 3260 (OH), 1660 (C=O), 1630 cm^{-1} ; $^1\text{H-nmr}$ (DMSO- d_6): δ 5.95 (s, 2H, O-CH₂-O), 4.82 (s, 1H, NH), 6.65-7.95 (m, 7H, phenyl protons), 9.43 (br s, 1H, COOH).

Anal. Calcd. for C₁₄H₁₁NO₄: C, 65.36; H, 4.32; N, 5.45. Found: C, 65.12; H, 4.01; N, 5.23.

2-(2'-Methylanilino)-4,5-methylenedioxybenzoic Acid (**3c**).

This compound was obtained in a yield of 25%, mp 153-155°; ir (potassium bromide): ν 3300 (OH), 1670 (COOH), 1640 cm^{-1} ; $^1\text{H-nmr}$ (DMSO- d_6): δ 2.26 (s, 3H, CH₃), 2.34 (s, 1H, NH), 6.03 (s, 2H, O-CH₂-O), 6.60-7.95 (m, 6H, phenyl protons), 9.83 (br s, 1H, COOH).

Anal. Calcd. for C₁₅H₁₃NO₄: C, 66.40; H, 4.84; N, 5.16. Found: C, 66.30; H, 4.95; N, 5.32.

2-(3'-Methylanilino)-4,5-methylenedioxybenzoic Acid (**3d**).

This compound was obtained in a yield of 21%, mp 150-153°; ir (potassium bromide): ν 3300 (OH), 1670 (C=O), 1630 cm^{-1} ; $^1\text{H-nmr}$ (DMSO- d_6): δ 2.33 (s, 3H, CH₃), 4.85 (s, 1H, NH), 6.02 (s, 2H, O-CH₂-O), 6.30-7.80 (m, 6H, phenyl protons), 9.52 (br s, 1H, COOH).

Anal. Calcd. for C₁₅H₁₃NO₄: C, 66.40; H, 4.84; N, 5.16. Found: C, 66.61; H, 4.62; N, 5.22.

2-(4'-Methylanilino)-4,5-methylenedioxybenzoic Acid (**3e**).

This compound was obtained in a yield of 23%, mp 163-165°; ir (potassium bromide): ν 3250 (OH), 1660 (C=O), 1635 cm^{-1} ; $^1\text{H-nmr}$ (DMSO- d_6): δ 2.32 (s, 3H, CH₃), 4.90 (s, 1H, NH), 5.88 (s, 2H, O-CH₂-O), 6.65-8.10 (m, 6H, phenyl protons), 9.65 (br s, 1H, COOH).

Anal. Calcd. for C₁₅H₁₃NO₄: C, 66.40; H, 4.84; N, 5.16. Found: C, 66.71; H, 4.98; N, 5.30.

2-(4'-Chloroanilino)-4,5-methylenedioxybenzoic Acid (**3f**).

This compound was obtained in a yield of 20%, mp 125-128°; ir (potassium bromide): ν 3320 (OH), 1660 (C=O), 1640 cm^{-1} ; $^1\text{H-nmr}$ (DMSO- d_6): δ 5.02 (s, 1H, NH), 6.03 (s, 2H, O-CH₂-O), 6.50-7.52 (m, 6H, phenyl protons), 9.82 (br s, 1H, COOH).

Anal. Calcd. for C₁₄H₁₀ClNO₄: C, 57.64; H, 3.46; N, 4.80; Cl, 12.15. Found: C, 57.30; H, 3.63; N, 5.10; Cl, 12.31.

2-(2'-Methoxyanilino)-4,5-methylenedioxybenzoic Acid (**3h**).

This compound was obtained in a yield of 23%, mp 133-135°; ir (potassium bromide): ν 3300 (OH), 1670 (C=O), 1630 cm^{-1} ; $^1\text{H-nmr}$ (DMSO- d_6): δ 3.80 (s, 3H, CH₃O), 5.09 (s, 1H, NH), 6.05 (s, 2H, O-CH₂-O), 6.40-8.00 (m, 6H, phenyl protons), 9.83 (br s, 1H, COOH).

Anal. Calcd. for C₁₅H₁₃NO₅: C, 62.71; H, 4.57; N, 4.88. Found: C, 62.55; H, 4.36; N, 4.74.

2-(3'-Methoxyanilino)-4,5-methylenedioxybenzoic Acid (**3j**).

This compound was obtained in a yield of 23%, mp 136-139°; ir (potassium bromide): ν 3350 (OH), 1680 (C=O), 1650 cm^{-1} ; $^1\text{H-nmr}$ (DMSO- d_6): δ 3.92 (s, 3H, CH₃O), 4.83 (s, 1H, NH), 6.03 (s, 2H, O-CH₂-O), 6.60-8.00 (m, 6H, phenyl protons), 9.58 (br s, 1H, COOH).

Anal. Calcd. for C₁₅H₁₃NO₅: C, 62.71; H, 4.57; N, 4.88. Found: C, 62.88; H, 4.64; N, 5.02.

2-(3',4'-Methylenedioxyanilino)-4-chlorobenzoic Acid (**6b**).

This compound was obtained in a yield of 21%, mp 159-162°; ir (potassium bromide): ν 3300 (OH), 1700 (C=O), 1650 cm^{-1} ;

$^1\text{H-nmr}$ (DMSO- d_6): δ 4.83 (s, 1H, NH), 5.99 (s, 2H, O-CH₂-O), 6.50-7.40 (m, 6H, phenyl protons), 9.58 (br s, 1H, COOH).

Anal. Calcd. for C₁₄H₁₀ClNO₄: C, 57.64; H, 3.46; N, 4.80; Cl, 12.15. Found: C, 57.80; H, 3.62; N, 4.57; Cl, 12.41.

2-(3',4'-Methylenedioxyanilino)-3-chlorobenzoic Acid (**6g**).

This compound was obtained in a yield of 20%, mp 163-165°; ir (potassium bromide): ν 3250 (OH), 1680 (C=O), 1630 cm^{-1} ; $^1\text{H-nmr}$ (DMSO- d_6): δ 4.93 (s, 1H, NH), 6.05 (s, 2H, O-CH₂-O), 6.65-7.90 (m, 5H, phenyl protons), 9.35 (br s, 1H, COOH).

Anal. Calcd. for C₁₄H₁₀ClNO₄: C, 57.64; H, 3.46; N, 4.80; Cl, 12.15. Found: C, 57.23; H, 3.17; N, 4.62; Cl, 12.02.

2-(3',4'-Methylenedioxyanilino)-5-methoxybenzoic Acid (**6i**).

This compound was obtained in a yield of 23%, mp 134-136°; ir (potassium bromide): ν 3300 (OH), 1700 (C=O), 1630 cm^{-1} ; $^1\text{H-nmr}$ (DMSO- d_6): δ 3.95 (s, 3H, CH₃O), 4.80 (s, 1H, NH), 6.05 (s, 2H, O-CH₂-O), 6.40-7.50 (m, 6H, phenyl protons), 9.90 (br s, 1H, COOH).

Anal. Calcd. for C₁₅H₁₃NO₅: C, 62.71; H, 4.57; N, 4.88. Found: C, 62.90; H, 4.82; N, 4.97.

General Procedure for the Preparation of Methylenedioxyacridines **9a-l** as shown in Scheme 1.

4'-[9-(2,3-Methylenedioxyacridinylamino)]methanesulfonyl-*m*-anisidine (**9a**).

A mixture of 2-anilino-4,5-methylenedioxybenzoic acid (**3a**) (3.5 g, 0.012 mole) and 20 ml of phosphoryl chloride was heated under reflux for 3 hours in an oil bath, and the excess phosphoryl chloride was removed under reduced pressure. The reaction mixture was cooled to room temperature, and then the contents were slowly added to a large excess of ice-ammonium hydroxide. Care was taken to maintain alkalinity until all the remaining phosphoryl chloride had undergone hydrolysis with ammonium hydroxide. The resulting reaction product was extracted with chloroform, washed with dilute ammonium hydroxide, and promptly dried with calcium chloride. The chloroform layer was separated and concentrated to give 9-chloro-2,3-methylenedioxyacridine (**7a**). Other substituted 4'-amino-9-chloro-2,3-methylenedioxyacridines **7** were used for the next reaction without further purification.

A mixture of 9-chloro-2,3-methylenedioxyacridine (**7a**) (1.0 g, 0.0039 mole) and methanesulfonyl-*m*-anisidine (0.56 g, 0.0039 mole) in 40 ml of ethanol was stirred at room temperature for 20 hours. At the end of this period the resulting red solid was filtered off and recrystallized from methanol-water (5:1, w/v) to give yellow crystals of **9a**, 1.5 g in 85% yield, mp >300° dec; ir (potassium bromide): ν 3830, 3740, 3400, 1640, 1610, 1570 cm^{-1} ; $^1\text{H-nmr}$ (DMSO- d_6): δ 3.08 (s, 3H, SO₂CH₃), 3.51 (s, 3H, CH₃O), 6.29 (s, 2H, O-CH₂-O), 7.00-8.20 (m, 9H, phenyl protons); ms: (m/e) 437 (M⁺), 358 (M⁺-SO₂CH₃).

Anal. Calcd. for C₂₂H₁₉N₃O₅S: C, 60.39; H, 4.39; N, 9.61; S, 7.33. Found: C, 60.12; H, 4.23; N, 9.43; S, 7.11.

4'-[9-(2,3-Methylenedioxy-6-chloroacridinylamino)]methanesulfonyl-*m*-anisidine (**9b**).

This compound was obtained in a yield of 75%, mp >300° dec; ir (potassium bromide): ν 3820, 3730, 3450, 1650, 1620, 1580 cm^{-1} ; $^1\text{H-nmr}$ (DMSO- d_6): δ 3.10 (s, 3H, SO₂CH₃), 3.48 (s, 3H, CH₃O), 6.32 (s, 2H, O-CH₂-O), 6.90-7.90 (m, 8H, phenyl protons).

Anal. Calcd. for C₂₂H₁₈ClN₃O₅S: C, 55.99; H, 3.85; Cl, 7.51; N, 8.91; S, 6.79. Found: C, 56.20; H, 3.63; Cl, 7.30; N, 8.73; S, 6.55.

4'-[9-(2,3-Methylenedioxy-5-methylacridinylamino)]methanesulfonyl-*m*-anisidine (**9c**).

This compound was in a yield of 85%, mp >300° dec; ir (potassium bromide): ν 3850, 3740, 3450, 1650, 1630, 1600 cm⁻¹; ¹H-nmr (DMSO-d₆): δ 2.51 (s, 3H, CH₃), 3.09 (s, 3H, SO₂CH₃), 3.51 (s, 3H, CH₃O), 6.30 (s, 2H, O-CH₂-O), 6.95-8.00 (m, 8H, phenyl protons).

Anal. Calcd. for C₂₃H₂₁N₃O₅S: C, 61.18; H, 4.70; N, 9.31; S, 7.10. Found: C, 61.40; H, 4.61; N, 9.15; S, 6.89.

4'-[9-(2,3-Methylenedioxy-6-methylacridinylamino)]methanesulfonyl-*m*-anisidine (**9d**).

This compound was obtained in a yield of 80%, mp >300° dec; ir (potassium bromide): ν 3850, 3740, 3430, 1700, 1640, 1610 cm⁻¹; ¹H-nmr (DMSO-d₆): δ 3.04 (s, 3H, CH₃), 3.09 (s, 3H, SO₂CH₃), 3.39 (s, 3H, CH₃O), 6.29 (s, 2H, O-CH₂-O), 6.80-8.00 (m, 8H, phenyl protons).

Anal. Calcd. for C₂₃H₂₁N₃O₅S: C, 61.18; H, 4.70; N, 9.31; S, 7.10. Found: C, 61.02; H, 4.39; N, 9.11; S, 6.98.

4'-[9-(2,3-Methylenedioxy-7-methylacridinylamino)]methanesulfonyl-*m*-anisidine (**9e**).

This compound was obtained in a yield of 85%, mp >300° dec; ir (potassium bromide): ν 3850, 3740, 3430, 1650, 1640, 1610 cm⁻¹; ¹H-nmr (DMSO-d₆): δ 2.33 (s, 3H, CH₃), 3.08 (s, 3H, SO₂CH₃), 3.48 (s, 3H, CH₃O), 6.28 (s, 2H, O-CH₂-O), 7.02-7.98 (m, 8H, phenyl protons).

Anal. Calcd. for C₂₃H₂₁N₃O₅S: C, 61.18; H, 4.70; N, 9.31; S, 7.10. Found: C, 61.01; H, 4.52; N, 9.18; S, 6.90.

4'-[9-(2,3-Methylenedioxy-7-chloroacridinylamino)]methanesulfonyl-*m*-anisidine (**9f**).

This compound was obtained in a yield of 70%, mp >300° dec; ir (potassium bromide): ν 3850, 3740, 3450, 1650, 1610, 1560 cm⁻¹; ¹H-nmr (DMSO-d₆): δ 3.09 (s, 3H, SO₂CH₃), 3.51 (s, 3H, CH₃O), 6.32 (s, 2H, O-CH₂-O), 7.00-8.20 (m, 8H, phenyl protons).

Anal. Calcd. for C₂₂H₁₈ClN₃O₅S: C, 55.99; H, 3.85; Cl, 7.51; N, 8.91; S, 6.79. Found: C, 55.71; H, 3.54; Cl, 7.29; N, 8.65; S, 6.50.

4'-[9-(2,3-Methylenedioxy-5-chloroacridinylamino)]methanesulfonyl-*m*-anisidine (**9g**).

This compound was obtained in a yield of 65%, mp >300°; ir (potassium bromide): ν 3850, 3730, 3420, 1640, 1610, 1550 cm⁻¹; ¹H-nmr (DMSO-d₆): δ 3.07 (s, 3H, SO₂CH₃), 3.51 (s, 3H, CH₃O), 6.31 (s, 2H, O-CH₂-O), 7.04-8.02 (m, 8H, phenyl protons).

Anal. Calcd. for C₂₂H₁₈ClN₃O₅S: C, 55.99; H, 3.85; Cl, 7.51; N, 8.91; S, 6.79. Found: C, 55.78; H, 3.78; Cl, 7.75; N, 8.79; S, 6.98.

4'-[9-(2,3-Methylenedioxy-5-methoxyacridinylamino)]methanesulfonyl-*m*-anisidine (**9h**).

This compound was obtained in a yield of 63%, mp >300° dec; ir (potassium bromide): ν 3830, 3730, 3500, 1650, 1610, 1580 cm⁻¹; ¹H-nmr (DMSO-d₆): δ 2.42 (s, 3H, CH₃O), 2.99 (s, 3H, SO₂CH₃), 3.40 (s, 3H, CH₃O), 6.23 (s, 2H, O-CH₂-O), 7.00-7.95 (m, 8H, phenyl protons).

Anal. Calcd. for C₂₃H₂₁N₃O₆S: C, 59.08; H, 4.54; N, 8.99; S, 6.86. Found: C, 58.89; H, 4.78; N, 9.21; S, 6.97.

4'-[9-(2,3-Methylenedioxy-7-methoxyacridinylamino)]methanesulfonyl-*m*-anisidine (**9i**).

This compound was obtained in a yield of 65%, mp >300° dec; ir (potassium bromide): ν 3850, 3740, 3520, 1650, 1620, 1550

cm⁻¹; ¹H-nmr (DMSO-d₆): δ 2.52 (s, 3H, CH₃O), 2.99 (s, 3H, SO₂CH₃), 3.44 (s, 3H, CH₃O), 6.21 (s, 2H, O-CH₂-O), 6.80-8.10 (m, 8H, phenyl protons).

Anal. Calcd. for C₂₃H₂₁N₃O₆S: C, 59.08; H, 4.54; N, 8.99; S, 6.86. Found: C, 58.89; H, 4.73; N, 8.72; S, 6.66.

4'-[9-(2,3-Methylenedioxy-6-methoxyacridinylamino)]methanesulfonyl-*m*-anisidine (**9j**).

This compound was obtained in a yield of 60%, mp >300° dec; ir (potassium bromide): ν 3850, 3740, 3430, 1630, 1600, 1520 cm⁻¹; ¹H-nmr (DMSO-d₆): δ 2.31 (s, 3H, CH₃O), 3.01 (s, 3H, SO₂CH₃), 3.43 (s, 3H, CH₃O), 6.30 (s, 2H, O-CH₂-O), 7.00-7.95 (m, 8H, phenyl protons).

Anal. Calcd. for C₂₃H₂₁N₃O₆S: C, 59.08; H, 4.54; N, 8.99; S, 6.86. Found: C, 59.35; H, 4.83; N, 9.03; S, 7.04.

9-(4-Methylanilino)-2,3-methylenedioxyacridine (**9k**).

This compound was in a yield of 90%, mp >300° dec; ir (potassium bromide): ν 3830, 3750, 3400, 1645, 1590, 1570 cm⁻¹; ¹H-nmr (DMSO-d₆): δ 3.05 (s, 3H, CH₃), 6.30 (s, 2H, O-CH₂-O), 7.18-8.22 (m, 10H, phenyl protons).

Anal. Calcd. for C₂₁H₁₆N₂O₂: C, 76.80; H, 4.92; N, 8.53. Found: C, 76.66; H, 4.79; N, 8.26.

9-Anilino-2,3-methylenedioxyacridine (**9l**).

This compound was in a yield of 90%, mp >300° dec; ir (potassium bromide): ν 3825, 3750, 3390, 1640, 1600, 1570 cm⁻¹; ¹H-nmr (DMSO-d₆): δ 6.30 (s, 2H, O-CH₂-O), 7.18-8.40 (m, 11H, phenyl protons).

Anal. Calcd. for C₂₀H₁₄N₂O₂: C, 76.41; H, 4.50; N, 8.91. Found: C, 76.38; H, 4.60; N, 8.79.

The physical data of 2-anilino-4,5-methylenedioxybenzoic acids **3a**, **3c-f**, **3h**, **3j**, **6b**, **6g**, **6i** and 9-anilino-2,3-methylenedioxyacridines **9a-l** are summarized in Table 1 and 2.

X-ray Crystallography.

The hydrochloride of the product **9a** was recrystallized by the slow evaporation of a methanol-water solution at room temperature. The crystal used for the X-ray measurement was a cleaved piece with approximate dimensions of 0.20 x 0.25 x 0.30 mm. The preliminary examination of the crystal which was carried out on a Rigaku automated four-circle diffractometer showed it to be triclinic with the space group P $\bar{1}$.

Crystal Data.

C₂₂H₁₉N₃O₅S·HCl (fw 473.96), triclinic P $\bar{1}$, *a* = 11.889(2), *b* = 11.701(2), *c* = 9.793(1) Å, α = 116.20(1), β = 76.27(1), γ = 107.89(1)°, *V* = 1155.03 Å³. *D*_c = 1.36 g/cm³ for *Z* = 2. The intensity data were collected at room temperature on a diffractometer utilizing nickel-filtered CuK α radiation (λ = 1.54178 Å). The θ - 2θ scan mode was employed for data collection. The scan rate was 6° min⁻¹ in 2θ , and the scan range in θ was varied by 1.2° + 0.15° tan θ . Backgrounds were counted for 5s at both ends of the scan with an offset of 50% of the scan range from the calculated position of the K α peak. The total of 3516 unique reflections was measured (2θ < 125°), of which 3224 were observed. The standard deviations in the structure amplitudes, σ (*F*_o), were derived from the counting statistics. Lorentz and polarization corrections were applied, but on absorption correction was made.

Solution and Refinement of the Structure.

The structure was solved by the direct method (MULTAN76)

[32], determining the phases of the 250 reflections with $|E_o| > 1.85$. The structure was refined by the block-diagonal least-squares method. The function minimized was $\sum w(|F_o| - |F_c|)^2$, where $w = 1$ for $0 < |F_o| \leq 20$ and $w = (20/|F_o|)^2$ for $|F_o| > 20$. An initial reflection using individual isotropic temperature factors for the non-hydrogen atoms led to a conventional $R = (\sum ||F_o| - |F_c||) / \sum |F_o|$ of 0.117. After successive refinement with anisotropic temperature factors for the non-hydrogen atoms, all the hydrogen atoms except for that of hydrogen chloride were readily located in the difference Fourier map; these atoms were then included in the further refinement with isotropic temperature factors. After the refinement was completed, the final values of R and $R_w = (\sum w(|F_o| - |F_c|)^2 / \sum w|F_o|^2)^{1/2}$ were 0.065 and 0.064 respectively. The final atomic positional and thermal parameters are given in Tables 4a-b. The atomic scattering factors for the S, O, and C atoms were taken from International Tables for X-Ray Crystallography (1974), while the factors for H were those of Stewart, Davidson and Simpson [33]. Computations were performed using the crystallographic program system UNICS [34], and program system made by one (M. K.) of the authors [35].

Biological Testing.

The biological test consisted of intraperitoneal inoculation of 2×10^5 L1210 cells into 18-25 g DBA/2 (SLC) hybrid mice on day 1. Drug treatment was initiated 24 hours later and continued for 6 days; drugs were administered twice daily by the intraperitoneal route on days 2, 4, and 6 to evaluate activity against the intraperitoneally implanted tumor. All administrations (10 mg/kg) were given in 10% chromophore suspension. Groups of six animals per dose level were used with one control group for every five tests. Average survivals (M. S. D.) were calculated in the usual way. The new medical results (T/C) are ratios of survival times of treated mice over control mice, expressed as a percent. T/C values were compared with control groups, and the results are recorded in Table 3.

Acknowledgement.

We are grateful to Dr. T. Taga Department of Pharmacy, Kyoto University for the use of computation programme of FACOM computer. We thank Dr. Tomokazu Yuizono and Dr. Hideya Yaginuma, Morishita Pharmaceutical Co., LTD. (1658 Oshinohara, Yasu-cho, Yasugun, Shiga 520-23, Japan) for the antitumor testing.

REFERENCES AND NOTES

- [1] M. Kimura, I. Okabayashi and A. Kato, *Chem. Pharm. Bull.*, **37**, 697 (1989).
- [2] J. W. Drake, The Molecular Basis of Mutation, HoldenDay Inc., San Francisco, 1970, p 134.
- [3] D. J. Patel, *J. Biopolymers*, **16**, 2739 (1977).
- [4] F. S. Parker and J. L. Irvin, *J. Biol. Chem.*, **199**, 889 (1952).
- [5] M. J. Waring, *Eur. J. Cancer*, **12**, 995 (1976).
- [6] L. S. Lerman, *Proc. Nat. Acad. Sci. U. S. A.*, **49**, 94 (1963).
- [7] W. J. Waring, *J. Chem. Ind.*, 105 (1975).
- [8] A. H. J. Wang, G. J. Quigley and A. Rich, *Nucl. Acid Res.*, **6**, 3879 (1979).
- [9] P. C. Courseille, B. Busetta and M. Hospital, *Acta Cryst.*, **B29**, 2349 (1973).
- [10] A. H. J. Wang, J. Nathans, G. Van der Marel, J. H. Van Boom and A. Rich, *Nature (London)*, **276**, 471 (1978).
- [11] C. C. Tsai, S. C. Jain and H. M. Sobell, *J. Mol. Biol.*, **114**, 301 (1977).
- [12] T. D. Sakore, B. S. Reddy and H. M. Sobell, *J. Mol. Biol.*, **135**, 763 (1979).
- [13] B. S. Reddy, T. P. Seshadri, T. D. Sakore and H. M. Sobell, *J. Mol. Biol.*, **135**, 787 (1979).
- [14] S. C. Jain, K. K. Bhandary and H. M. Sobell, *J. Mol. Biol.*, **135**, 813 (1979).
- [15] J. W. Drake and R. H. A. Baltz, *Rev. Biochem.*, **20**, 11 (1976).
- [16] J. R. Roth, *Rev. Genet.*, **8**, 319 (1974).
- [17] F. H. C. Crick, L. Barnett, S. Brenner and R. J. Watts-Tobin, *Nature (London)*, **192**, 1227 (1961).
- [18] J. C. Wang, *J. Mol. Biol.*, **89**, 783 (1974).
- [19] M. Waring, *J. Mol. Biol.*, **54**, 247 (1976).
- [20] B. F. Cain and G. J. Atwell, *Eur. J. Cancer*, **10**, 539 (1974).
- [21] N. B. Fulong, J. Sato, T. Brown, F. Chavez and R. B. Hurlbert, *Cancer Res.*, **38**, 1329 (1978).
- [22] S. S. Legha, J. U. Gutterman, S. W. Hall, R. S. Benjamin, M. A. Burgess, M. Valdivieso and G. P. Bodey, *Cancer Res.*, **38**, 3712 (1978).
- [23] H. Surrey, Name Reactions in Organic Chemistry, Academic Press, New York, 1961, p 236.
- [24] A. Acheson, Acridines, Interscience Division, John Wiley and Sons, New York, 1956, p 148.
- [25] A. M. B. Orr, R. Robinson and M. M. Williams, *J. Chem. Soc.*, **111**, 948 (1917).
- [26] A. Albert, The Acridines, 2nd Ed, Edward Arnold, London, 1966, p 403.
- [27] C. K. Johnson, ORTEP II, Report ORNL-5138, Oak Ridge National Laboratory, Tennessee (1976).
- [28] H. L. Carrell, *Acta Cryst., Sect. B*, **28**, 1754 (1972).
- [29] J. P. Glusker, J. A. Minkin and W. Orehowsky, Jr., *Acta Cryst., Sect. B*, **28**, 1 (1972).
- [30] H. M. Berman and J. P. Glusker, *Acta Cryst., Sect. B*, **28**, 590 (1972).
- [31] J. P. Glusker, B. Gallen and H. L. Carrell, *Acta Cryst., Sect. B*, **29**, 2000 (1973).
- [32] G. Germain, P. Main and M. M. Woolfson, *Acta Cryst., Sect. A*, **27**, 368 (1971).
- [33] R. F. Stewart, E. R. Davidson and W. T. Simpson, *J. Chem. Phys.*, **42**, 3175 (1965).
- [34] T. Ashida and N. Yasuoka, UNICS-Osaka, The Computation Center, Osaka Univ, 1979.
- [35] M. Kimura, *J. Chem. Soc., Perkin Trans. II*, 205 (1987).
- [36] W. C. Hamilton, *Acta Cryst.*, **12**, 609 (1959).
- [37] J. M. Karle and R. L. Cysyk, *Acta Cryst.*, **B36**, 3012 (1980).